Attorney General Dustin McDaniel said Monday that Arkansas will receive $1.56 million of a $90 million settlement reached between GlaxoSmithKline LLC and 38 attorneys general to resolve allegations that the pharmaceutical manufacturer unlawfully promoted its diabetes drug, Avandia.
McDaniel said he filed a consent judgment in Pulaski County Circuit Court on Thursday to settle claims that GlaxoSmithKline illegally marketed Avandia by misrepresenting its safety risks related to heart attacks and strokes.
As part of the settlement, GlaxoSmithKline will be barred from making false, misleading or deceptive claims about any diabetes drugs. Claims about the safety of its drugs compared to others must be supported by substantial evidence or clinical experience. GSK must also make available to the public summaries of the results of all studies of its diabetes drugs.
The company admitted no wrongdoing.